[HTML] springer.com

[HTML][HTML] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer chemotherapy and …, 2010 - Springer
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
被引用次数：39 相关文章
[PDF] academia.edu

[PDF][PDF] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer Chemother …, 2010 - academia.edu
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.

MK Wong, AI Lo, B Lam, WK Lam… - Cancer …, 2010 - search.ebscohost.com
Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC).
Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR-TKI), has …

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.

MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer Chemotherapy …, 2009 - europepmc.org
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR …

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer Chemotherapy …, 2010 - infona.pl
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

MK Wong, AI Lo, B Lam, WK Lam… - Cancer …, 2010 - pubmed.ncbi.nlm.nih.gov
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR …
[PDF] psu.edu

[PDF][PDF] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer Chemother …, 2010 - Citeseer
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
[PDF] researchgate.net

[PDF][PDF] Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer Chemother …, 2010 - researchgate.net
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
[PDF] core.ac.uk

[PDF][PDF] Erlotinib as salvage treatment after failure to first-line Gefitinib in

MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer Chemotherapy …, 2010 - core.ac.uk
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

MK Wong, AI Lo, B Lam, WK Lam… - Cancer Chemotherapy …, 2010 - search.proquest.com
Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC).
Gefitinib, an epidermal growth factor receptor--tyrosine kinase inhibitor (EGFR-TKI), has …